ClinicalTrials.Veeva

Menu
A

Austin Research Center for Retina | Austin, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
GT005
Ranibizumab
KSI-301
Fenofibrate
EYP-1901
ANX007
AR-14034
Tarcocimab
ONL1204

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 27 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Enrolling
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.

Active, not recruiting
Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabeti...

Not yet enrolling
Macular Edema
Drug: BI 1815368
Drug: Placebo

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular de...

Active, not recruiting
Age-Related Macular Degeneration
Nonexudative Age-related Macular Degeneration
Device: i-Lumen(TM) AMD
Device: i-Lumen(TM) AMD Sham

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Choroidal Neovascularization
Wet Age-related Macular Degeneration
Genetic: ABBV-RGX-314
Biological: Ranibizumab (LUCENTIS®)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Drug: AR-14034 SR implant lower dose
Drug: AR-14034 SR implant higher dose

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling
Macular Degeneration
Drug: Ranibizumab
Drug: Zifibancimig
Status recently updated

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Enrolling
Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Trial sponsors

Kodiak Sciences logo
Boehringer Ingelheim logo
Roche logo
AbbVie logo
G
Jaeb Center for Health Research logo
4
Alcon logo
A
Bayer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems